Table 3 Response rates according to RECIST 1.0 and mRECIST

From: A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma

Response

TAE N =38 (%)

sTACE N =43(%)

Response (EOT)

PR

5 (13.2)

14 (32.6)

SD

18 (47.4)

21 (48.8)

PD

10 (26.3)

3 (7.0)

Missing

5 (13.2)

5 (11.6)

*P=0.04

  

Best response

PR

9 (23.7)

18 (41.9)

SD

15 (39.5)

17 (38.5)

PD

10 (26.3)

3 (7.0)

Missing

4 (10.5)

5 (11.6)

*P=0.08

  

mRECIST response (EOT)

CR

7 (18.4)

13 (30.2)

PR

11 (28.9)

16 (37.2)

SD

4 (10.5)

6 (14.0)

PD

6 (15.8)

2 (4.7)

Missing

10 (26.3)

6 (14.0)

*P=0.068

  
  1. Abbreviations: CR=complete response; EOT=end of treatment; PD=progressive disease; PR=partial response; sTACE=
  2. Chi-squared response (CR, PR) vs no response (SD, PD, missing).
Back to article page